Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 2
1965 1
1996 1
1997 2
1998 1
2000 1
2001 1
2003 1
2004 1
2006 1
2008 1
2009 1
2010 1
2011 5
2012 2
2013 4
2014 5
2015 6
2016 4
2017 6
2018 4
2019 1
2020 6
2021 10
2022 6
2023 5
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Réactualisation de la méthode française d'imputabilité des effets indésirables des médicaments.
Cercle de Réflexion sur l’Imputabilité (CRI); Arimone Y, Bidault I, Dutertre JP, Gérardin M, Guy C, Haramburu F, Hillaire-Buys D, Meglio C, Penfornis C, Théophile H, Valnet-Rabier MB. Cercle de Réflexion sur l’Imputabilité (CRI), et al. Among authors: gerardin m. Therapie. 2011 Nov-Dec;66(6):517-25. doi: 10.2515/therapie/2011073. Therapie. 2011. PMID: 27393472 French.
Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.
Bouazza N, Urien S, Foissac F, Choupeaux L, Lui G, Froelicher Bournaud L, Rouillon S, Zheng Y, Bardin E, Stremler N, Bessaci K, Bihouee T, Coirier-Duet E, Marguet C, Deneuville E, Laurans M, Reix P, Gerardin M, Mittaine M, Epaud R, Thumerelle C, Weiss L, Berthaud R, Semeraro M, Treluyer JM, Benaboud S, Sermet-Gaudelus I. Bouazza N, et al. Among authors: gerardin m. Clin Pharmacokinet. 2024 Mar;63(3):333-342. doi: 10.1007/s40262-023-01342-3. Epub 2024 Feb 4. Clin Pharmacokinet. 2024. PMID: 38310629
Parachuting: a dangerous trend in recreational psychoactive substance delivery.
Boels D, Grall-Bronnec M, Guerlais M, Le Roux G, Spiers A, Gerardin M, Lomenech H, Bretaudeau-Deguigne M, Daveluy A, Turcant A, Jolliet P, Victorri-Vigneau C. Boels D, et al. Among authors: gerardin m. Expert Opin Drug Deliv. 2017 Apr;14(4):491-498. doi: 10.1080/17425247.2016.1222371. Epub 2016 Aug 22. Expert Opin Drug Deliv. 2017. PMID: 27546356 Review.
An update on zolpidem abuse and dependence.
Victorri-Vigneau C, Gérardin M, Rousselet M, Guerlais M, Grall-Bronnec M, Jolliet P. Victorri-Vigneau C, et al. Among authors: gerardin m. J Addict Dis. 2014;33(1):15-23. doi: 10.1080/10550887.2014.882725. J Addict Dis. 2014. PMID: 24467433 Review.
Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis.
Leroy C, Spelier S, Essonghe NC, Poix V, Kong R, Gizzi P, Bourban C, Amand S, Bailly C, Guilbert R, Hannebique D, Persoons P, Arhant G, Prévotat A, Reix P, Hubert D, Gérardin M, Chamaillard M, Prevarskaya N, Rebuffat S, Shapovalov G, Beekman J, Lejeune F. Leroy C, et al. Among authors: gerardin m. Mol Ther. 2023 Apr 5;31(4):970-985. doi: 10.1016/j.ymthe.2023.01.014. Epub 2023 Jan 14. Mol Ther. 2023. PMID: 36641622 Free PMC article.
Nitrous oxide: a unique official French addictovigilance national survey.
Guerlais M, Aquizerate A, Lionnet A, Daveluy A, Duval M, Gérardin M, Istvan M, Laforgue EJ, Victorri-Vigneau C; for French Addictovigilance Network. Guerlais M, et al. Among authors: gerardin m. Front Public Health. 2023 May 3;11:1167746. doi: 10.3389/fpubh.2023.1167746. eCollection 2023. Front Public Health. 2023. PMID: 37206871 Free PMC article.
Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study.
Semenchuk J, Naito Y, Charman SC, Carr SB, Cheng SY, Marshall BC, Faro A, Elbert A, Gutierrez HH, Goss CH, Karadag B, Burgel PR, Colombo C, Salvatore M, Padoan R, Daneau G, Harutyunyan S, Kashirskaya N, Kirwan L, Middleton PG, Ruseckaite R, de Monestrol I, Naehrlich L, Mondejar-Lopez P, Jung A, van Rens J, Bakkeheim E, Orenti A, Zomer-van Ommen D, da Silva-Filho LVR, Fernandes FF, Zampoli M, Stephenson AL; Global CF Registry Collaboration. Semenchuk J, et al. J Cyst Fibros. 2024 Sep;23(5):815-822. doi: 10.1016/j.jcf.2024.07.019. Epub 2024 Aug 26. J Cyst Fibros. 2024. PMID: 39191560 Free article.
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C; French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC. Am J Respir Crit Care Med. 2021. PMID: 33600738
[Update of the French drug reaction assessment method].
Cercle de Reflexion sur l'Imputabilite; Arimone Y, Bidault I, Dutertre JP, Gérardin M, Guy C, Haramburu F, Hillaire-Buys D, Meglio C, Penfornis C, Théophile H, Valnet-Rabier MB. Cercle de Reflexion sur l'Imputabilite, et al. Among authors: gerardin m. Therapie. 2011 Nov-Dec;66(6):517-25. doi: 10.2515/therapie/2011073. Epub 2011 Dec 21. Therapie. 2011. PMID: 22186077 Review. French.
77 results